NCT00817219View on ClinicalTrials.gov

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Psoriasis Vulgaris
Interventions
DRUG

Calcipotriene plus betamethasone dipropionate ointment

Once daily application for 4 weeks

Trial Locations (8)

23507

Virginia Clinical Research, Inc., Norfolk

32751

Ameriderm Research, Maitland

76011

Arlington Research Center, Arlington

77030

University of Texas-Dermatology, Houston

92123

University of California at San Diego/Rady Children's Hospital, San Diego

94538

Center for Dermatology Clinical Research, Fremont

98101

DBA Dermatology Associates, Seattle

60611-2997

Northwestern University's Feinberg School of Medicine, Chicago

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT00817219 - Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris | Biotech Hunter | Biotech Hunter